Stereotaxis, Inc. (AMEX: STXS) Stock Competitors & Peer Comparison
See STXS's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for STXS and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STXS | $1.36 | +1.88% | 129.3M | -7.76 | -$0.17 | N/A |
| ISRG | $385.13 | +1.90% | 133.2B | 39.21 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.13% |
| BDX | $184.20 | +0.71% | 51.2B | 14.30 | $13.00 | +2.13% |
| RMD | $227.67 | +2.10% | 33.3B | 21.32 | $10.77 | +1.06% |
| MDLN | $33.50 | +2.78% | 27.2B | 23.53 | $1.36 | N/A |
| WST | $361.98 | +1.91% | 25.7B | 42.93 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.53 | +0.79% | 15.6B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.13% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
STXS vs ISRG Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, ISRG has a market cap of 133.2B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while ISRG trades at $385.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas ISRG's P/E ratio is 39.21. In terms of profitability, STXS's ROE is -1.33%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, STXS is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for STXS.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
STXS vs BDXA Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas BDXA's P/E ratio is 45.70. In terms of profitability, STXS's ROE is -1.33%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, STXS is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for STXS.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
STXS vs BDX Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, BDX has a market cap of 51.2B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while BDX trades at $184.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas BDX's P/E ratio is 14.30. In terms of profitability, STXS's ROE is -1.33%, compared to BDX's ROE of +0.04%. Regarding short-term risk, STXS is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for STXS.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
STXS vs RMD Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, RMD has a market cap of 33.3B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while RMD trades at $227.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas RMD's P/E ratio is 21.32. In terms of profitability, STXS's ROE is -1.33%, compared to RMD's ROE of +0.24%. Regarding short-term risk, STXS is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for STXS.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
STXS vs MDLN Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, MDLN has a market cap of 27.2B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while MDLN trades at $33.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas MDLN's P/E ratio is 23.53. In terms of profitability, STXS's ROE is -1.33%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, STXS is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for STXS.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
STXS vs WST Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while WST trades at $361.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas WST's P/E ratio is 42.93. In terms of profitability, STXS's ROE is -1.33%, compared to WST's ROE of +0.19%. Regarding short-term risk, STXS is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for STXS.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
STXS vs HOLX Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas HOLX's P/E ratio is 31.54. In terms of profitability, STXS's ROE is -1.33%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, STXS is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for STXS.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
STXS vs SOLV Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, SOLV has a market cap of 15.6B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while SOLV trades at $90.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas SOLV's P/E ratio is 12.69. In terms of profitability, STXS's ROE is -1.33%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, STXS is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for STXS.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
STXS vs BDXB Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas BDXB's P/E ratio is 7.60. In terms of profitability, STXS's ROE is -1.33%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, STXS is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for STXS.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
STXS vs BAX Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while BAX trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas BAX's P/E ratio is 11.39. In terms of profitability, STXS's ROE is -1.33%, compared to BAX's ROE of -0.17%. Regarding short-term risk, STXS is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for STXS.Check BAX's competition here
Avantor, Inc. (NYSE: AVTR)
STXS vs AVTR Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while AVTR trades at $15.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas AVTR's P/E ratio is 18.15. In terms of profitability, STXS's ROE is -1.33%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, STXS is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for STXS.Check AVTR's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
STXS vs COO Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, COO has a market cap of 10.4B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while COO trades at $54.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas COO's P/E ratio is 11.68. In terms of profitability, STXS's ROE is -1.33%, compared to COO's ROE of +0.07%. Regarding short-term risk, STXS is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for STXS.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
STXS vs RGEN Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, RGEN has a market cap of 9.9B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while RGEN trades at $174.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas RGEN's P/E ratio is 97.07. In terms of profitability, STXS's ROE is -1.33%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, STXS is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for STXS.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
STXS vs ATR Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, ATR has a market cap of 8B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while ATR trades at $125.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas ATR's P/E ratio is 21.79. In terms of profitability, STXS's ROE is -1.33%, compared to ATR's ROE of +0.14%. Regarding short-term risk, STXS is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for STXS.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
STXS vs BLCO Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while BLCO trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas BLCO's P/E ratio is 26.52. In terms of profitability, STXS's ROE is -1.33%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, STXS is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for STXS.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
STXS vs STVN Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while STVN trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas STVN's P/E ratio is 32.57. In terms of profitability, STXS's ROE is -1.33%, compared to STVN's ROE of +0.09%. Regarding short-term risk, STXS is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for STXS.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
STXS vs TFX Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while TFX trades at $129.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas TFX's P/E ratio is 14.75. In terms of profitability, STXS's ROE is -1.33%, compared to TFX's ROE of -0.32%. Regarding short-term risk, STXS is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for STXS.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
STXS vs MMSI Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while MMSI trades at $86.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas MMSI's P/E ratio is 22.04. In terms of profitability, STXS's ROE is -1.33%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, STXS is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for STXS.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
STXS vs NVST Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, NVST has a market cap of 4B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while NVST trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas NVST's P/E ratio is 16.85. In terms of profitability, STXS's ROE is -1.33%, compared to NVST's ROE of +0.04%. Regarding short-term risk, STXS is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for STXS.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
STXS vs ICUI Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while ICUI trades at $158.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas ICUI's P/E ratio is 19.46. In terms of profitability, STXS's ROE is -1.33%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, STXS is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for STXS.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
STXS vs PLSE Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while PLSE trades at $49.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas PLSE's P/E ratio is -46.78. In terms of profitability, STXS's ROE is -1.33%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, STXS is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for STXS.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
STXS vs ATRC Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, ATRC has a market cap of 2.9B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while ATRC trades at $56.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas ATRC's P/E ratio is 1745.96. In terms of profitability, STXS's ROE is -1.33%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, STXS is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for STXS.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
STXS vs XRAY Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while XRAY trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas XRAY's P/E ratio is 6.87. In terms of profitability, STXS's ROE is -1.33%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, STXS is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for STXS.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
STXS vs LMAT Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while LMAT trades at $80.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas LMAT's P/E ratio is 29.69. In terms of profitability, STXS's ROE is -1.33%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, STXS is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for STXS.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
STXS vs BLFS Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while BLFS trades at $36.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas BLFS's P/E ratio is -172.18. In terms of profitability, STXS's ROE is -1.33%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, STXS is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for STXS.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
STXS vs AZTA Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while AZTA trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas AZTA's P/E ratio is 78.64. In terms of profitability, STXS's ROE is -1.33%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, STXS is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for STXS.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
STXS vs KMTS Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while KMTS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas KMTS's P/E ratio is -9.50. In terms of profitability, STXS's ROE is -1.33%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, STXS is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for STXS.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
STXS vs STAA Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while STAA trades at $22.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas STAA's P/E ratio is 39.38. In terms of profitability, STXS's ROE is -1.33%, compared to STAA's ROE of +0.01%. Regarding short-term risk, STXS is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for STXS.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
STXS vs ATRI Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas ATRI's P/E ratio is 64.50. In terms of profitability, STXS's ROE is -1.33%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, STXS is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for STXS.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
STXS vs ANGO Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, ANGO has a market cap of 648.1M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while ANGO trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas ANGO's P/E ratio is -40.21. In terms of profitability, STXS's ROE is -1.33%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, STXS is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for STXS.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
STXS vs SMTI Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, SMTI has a market cap of 322.8M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while SMTI trades at $35.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas SMTI's P/E ratio is -585.17. In terms of profitability, STXS's ROE is -1.33%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, STXS is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for STXS.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
STXS vs EMBC Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, EMBC has a market cap of 302M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while EMBC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas EMBC's P/E ratio is 1.96. In terms of profitability, STXS's ROE is -1.33%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, STXS is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for STXS.Check EMBC's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
STXS vs NNNN Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, NNNN has a market cap of 241.8M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while NNNN trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas NNNN's P/E ratio is 79.62. In terms of profitability, STXS's ROE is -1.33%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, STXS is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for STXS.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
STXS vs OSUR Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, OSUR has a market cap of 238.2M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while OSUR trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas OSUR's P/E ratio is -5.01. In terms of profitability, STXS's ROE is -1.33%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, STXS is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for STXS.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
STXS vs UTMD Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, UTMD has a market cap of 237.6M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while UTMD trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas UTMD's P/E ratio is 22.08. In terms of profitability, STXS's ROE is -1.33%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, STXS is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for STXS.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
STXS vs PDEX Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, PDEX has a market cap of 213.6M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while PDEX trades at $72.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas PDEX's P/E ratio is 16.20. In terms of profitability, STXS's ROE is -1.33%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, STXS is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for STXS.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
STXS vs KRMD Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while KRMD trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas KRMD's P/E ratio is -79.00. In terms of profitability, STXS's ROE is -1.33%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, STXS is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for STXS.Check KRMD's competition here
Daxor Corporation (NASDAQ: DXR)
STXS vs DXR Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, DXR has a market cap of 68M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while DXR trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas DXR's P/E ratio is 9.47. In terms of profitability, STXS's ROE is -1.33%, compared to DXR's ROE of +0.13%. Regarding short-term risk, STXS is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for STXS.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
STXS vs AKYA Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas AKYA's P/E ratio is -1.34. In terms of profitability, STXS's ROE is -1.33%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, STXS is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for STXS.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
STXS vs STSS Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas STSS's P/E ratio is -0.02. In terms of profitability, STXS's ROE is -1.33%, compared to STSS's ROE of -1.54%. Regarding short-term risk, STXS is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for STXS.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
STXS vs OMIC Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas OMIC's P/E ratio is -0.58. In terms of profitability, STXS's ROE is -1.33%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, STXS is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for STXS.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
STXS vs IGAP Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas IGAP's P/E ratio is -10.52. In terms of profitability, STXS's ROE is -1.33%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, STXS is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for STXS.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
STXS vs NEPH Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, NEPH has a market cap of 46.6M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while NEPH trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas NEPH's P/E ratio is 71.50. In terms of profitability, STXS's ROE is -1.33%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, STXS is more volatile compared to NEPH. This indicates higher risk in terms of short-term price fluctuations for STXS.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
STXS vs POCI Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, POCI has a market cap of 46.1M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while POCI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas POCI's P/E ratio is -6.68. In terms of profitability, STXS's ROE is -1.33%, compared to POCI's ROE of -0.37%. Regarding short-term risk, STXS is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for STXS.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
STXS vs HBIO Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, HBIO has a market cap of 36M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while HBIO trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas HBIO's P/E ratio is -22.17. In terms of profitability, STXS's ROE is -1.33%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, STXS is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for STXS.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
STXS vs MLSS Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, MLSS has a market cap of 35.5M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while MLSS trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas MLSS's P/E ratio is -8.02. In terms of profitability, STXS's ROE is -1.33%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, STXS is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for STXS.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
STXS vs SDC Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas SDC's P/E ratio is -0.03. In terms of profitability, STXS's ROE is -1.33%, compared to SDC's ROE of -1.96%. Regarding short-term risk, STXS is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for STXS.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
STXS vs IVC Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas IVC's P/E ratio is -0.79. In terms of profitability, STXS's ROE is -1.33%, compared to IVC's ROE of -0.46%. Regarding short-term risk, STXS is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for STXS.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
STXS vs RVP Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while RVP trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas RVP's P/E ratio is -5.67. In terms of profitability, STXS's ROE is -1.33%, compared to RVP's ROE of -0.05%. Regarding short-term risk, STXS is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for STXS.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
STXS vs BNGO Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, BNGO has a market cap of 17.9M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while BNGO trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas BNGO's P/E ratio is -0.36. In terms of profitability, STXS's ROE is -1.33%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, STXS is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for STXS.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
STXS vs ZJYL Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while ZJYL trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, STXS's ROE is -1.33%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, STXS is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for STXS.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
STXS vs RGNT Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, RGNT has a market cap of 12.6M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas RGNT's P/E ratio is -0.07. In terms of profitability, STXS's ROE is -1.33%, compared to RGNT's ROE of N/A. Regarding short-term risk, STXS is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for STXS.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
STXS vs CUPR Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, CUPR has a market cap of 7.9M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while CUPR trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas CUPR's P/E ratio is -2.12. In terms of profitability, STXS's ROE is -1.33%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, STXS is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for STXS.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
STXS vs FEMY Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, FEMY has a market cap of 7.7M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while FEMY trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas FEMY's P/E ratio is -0.57. In terms of profitability, STXS's ROE is -1.33%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, STXS is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for STXS.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
STXS vs LUCY Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, LUCY has a market cap of 5.2M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while LUCY trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas LUCY's P/E ratio is -0.49. In terms of profitability, STXS's ROE is -1.33%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, STXS is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for STXS.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
STXS vs NSTG Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas NSTG's P/E ratio is -0.03. In terms of profitability, STXS's ROE is -1.33%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, STXS is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for STXS.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
STXS vs POAI Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas POAI's P/E ratio is -0.03. In terms of profitability, STXS's ROE is -1.33%, compared to POAI's ROE of -21.19%. Regarding short-term risk, STXS is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for STXS.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
STXS vs MHUA Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas MHUA's P/E ratio is 0.25. In terms of profitability, STXS's ROE is -1.33%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, STXS is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for STXS.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
STXS vs NXGL Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, NXGL has a market cap of 2.4M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while NXGL trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas NXGL's P/E ratio is -0.40. In terms of profitability, STXS's ROE is -1.33%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, STXS is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for STXS.Check NXGL's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
STXS vs GMVD Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas GMVD's P/E ratio is -0.01. In terms of profitability, STXS's ROE is -1.33%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, STXS is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for STXS.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
STXS vs GMVDW Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas GMVDW's P/E ratio is N/A. In terms of profitability, STXS's ROE is -1.33%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, STXS is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for STXS.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
STXS vs AVGR Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas AVGR's P/E ratio is -0.05. In terms of profitability, STXS's ROE is -1.33%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, STXS is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for STXS.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
STXS vs NXGLW Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, NXGLW has a market cap of 1.2M. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, STXS's ROE is -1.33%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, STXS is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for STXS.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
STXS vs LUCYW Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas LUCYW's P/E ratio is N/A. In terms of profitability, STXS's ROE is -1.33%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, STXS is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for STXS.Check LUCYW's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
STXS vs HRC Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, HRC has a market cap of 0. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas HRC's P/E ratio is 41.92. In terms of profitability, STXS's ROE is -1.33%, compared to HRC's ROE of +0.14%. Regarding short-term risk, STXS is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for STXS.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
STXS vs ALOG Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas ALOG's P/E ratio is 40.93. In terms of profitability, STXS's ROE is -1.33%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, STXS is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for STXS.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
STXS vs IVTY Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas IVTY's P/E ratio is -3.80. In terms of profitability, STXS's ROE is -1.33%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, STXS is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for STXS.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
STXS vs ATRS Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas ATRS's P/E ratio is 14.95. In terms of profitability, STXS's ROE is -1.33%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, STXS is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for STXS.Check ATRS's competition here
Apria, Inc. (NASDAQ: APR)
STXS vs APR Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, APR has a market cap of 0. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas APR's P/E ratio is 22.59. In terms of profitability, STXS's ROE is -1.33%, compared to APR's ROE of +9.81%. Regarding short-term risk, STXS is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for STXS.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
STXS vs IIN Comparison September 2026
Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STXS stands at 129.3M. In comparison, IIN has a market cap of 0. Regarding current trading prices, STXS is priced at $1.36 on the AMEX, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STXS currently has a P/E ratio of -7.76, whereas IIN's P/E ratio is 226.45. In terms of profitability, STXS's ROE is -1.33%, compared to IIN's ROE of -0.00%. Regarding short-term risk, STXS is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for STXS.Check IIN's competition here